Core Insights - TransCode Therapeutics has initiated dosing of the first patient in Cohort 3 of its Phase 1 clinical trial for TTX-MC138, following approval from the Safety Review Committee based on positive safety data from earlier cohorts [1][2][3] - The dosing in Cohort 3 is approximately double that of Cohort 2, with ongoing analyses indicating a favorable pharmacokinetic and pharmacodynamic profile consistent with preclinical results [2][4] - TTX-MC138 is designed to inhibit microRNA-10b, which is implicated in the progression of metastatic cancers, and has shown promising results in previous trials [4][7] Company Overview - TransCode Therapeutics is focused on developing RNA therapeutics for treating metastatic diseases, utilizing its proprietary TTX nanoparticle platform [7] - The company’s lead candidate, TTX-MC138, targets tumors that overexpress microRNA-10b, a known biomarker for metastasis [7] - TransCode has a portfolio of first-in-class RNA therapeutic candidates aimed at overcoming RNA delivery challenges to access novel genetic targets for cancer treatment [7] Clinical Trial Details - The Phase 1 clinical trial is a multicenter, open-label study designed to evaluate the safety and tolerability of TTX-MC138 in patients with various metastatic solid cancers [5] - The trial consists of a dose-escalation stage followed by a dose-expansion stage, with the primary objective of assessing safety and tolerability [5] - Preliminary results from the trial may provide early evidence of clinical activity for TTX-MC138, although this is not a primary endpoint [5]
TransCode Therapeutics Announces First Patient Dosed in Third Cohort with Lead Candidate in Phase 1 Clinical Trial